Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients

Kidney International

Volumn 65, Issue 4, 2004, Pages 1440-1448

  Schmitt, Wilhelm H ^b   Hagen, E Christiaan ^c   Neumann, Irmgard ^c   Nowack, Rainer ^c   Flores Suárez, Luis Felipe ^a   Van Der Woude, Fokko J ^c  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NONE

Author keywords

Antineutrophil cytoplasmic antibodies (ANCA); Antithymocyte globulin (ATG); Vasculitis; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABSCESS; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BONE MARROW DEPRESSION; CAUSE OF DEATH; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERABILITY; FEVER; FOLLOW UP; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JAUNDICE; LUNG HEMORRHAGE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RELAPSE; REMISSION; SERUM SICKNESS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEGENER GRANULOMATOSIS;

EID: 1642545105     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00534.x     Document Type: Article

References (48)

1. HOFFMAN GS, KERR GS, LEAVITT RY, et al: Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488, 1992
2. REINHOLD-KELLER E, BEUGE N, LATZA U, et al: An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Arthritis Rheum 43:1021-1032, 2000
3. JAYNE DRW: Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis. Cleve Clin J Med 69 (Suppl 2):SII 110-115, 2002
4. FRANSSEN CFM, STEGEMAN CA, KALLENBERG CGM, et al: Antiproteinase 3- and antimyeloperoxidase associated vasculitis. Kidney Int 57:2195-2206, 2000
5. HARPER L, SAVAGE COS: Pathogenesis of ANCA-associated vasculitis. J Pathol 190:349-359, 2000
6. BOLTON WK, INNES D, STURGILL BC, KAISER DL: T cells and macrophages in rapidly progressive glomerulonephritis: Clinico-pathological correlates. Kidney Int 32:869-876, 1987
7. CSERNOK E, TRABANDT A, MÜLLER A, et al: Cytokine profiles in Wegener's granulomatosis: predominace of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42:742-750, 1999
8. BALDING CEJ, HOWIE AJ, DRAKE-LEE AB, SAVAGE COS: Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 125:332-339, 2001
9. KOMOCSI A, LAMPRECHT P, CSERNOK E, et al: Peripheral blood and granuloma CD4+ CD28- T cells are a major source of interferon-γ and tumor necrosis factor-α in Wegener's granulomatosis. Am J Pathol 160:1717-1724, 2002
10. CUNNINGHAM MA, HUANG XR, DOWLING JP, et al: Effectors of cell-mediated immunity are prominent in "pauci-immune" glomerulonephritis. J Am Soc Nephrol 10:499-506, 1999
11. LAMPRECHT P, MOOSIG F, CSERNOK E, et al: CD28 negative T cells are enriched in the granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 56:751-757, 2001
12. VAN DER WOUDE FJ, VAN ES LA, DAHA MR: The role of c-ANCA antigen in the pathogenesis of Wegener's granulomatosis. A hypothesis based on both humeral and cellular mechanisms. Neth J Med 36:169-171, 1990
13. BROUWER E, STEGEMAN C, MUITEMA M, et al: T-cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis. Clin Exp Immunol 98:448-453, 1994
14. KING WJ, BROOKS CJ, HOLDER R, et al: T lymphocyte responses to anti-neutrophil cytoplasmic antibody (ANCA) antigens are present in patients with ANCA associated systemic vasculitis and persist during disease remission. Cin Exp Immunol 112:539-546, 1998
15. + T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10. J Immunol 160:3602-3609, 1998
16. SCHMITT WH, HEESEN C, CSERNOK E, et al: Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthritis Rheum 35:1088-1096, 1992
17. WANG G, CSERNOK E, GROSS WL: High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 102:517-523, 1997
18. LOCKWOOD CM, THIRU S, ISAACS J, et al: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341:1620, 1993
19. MATHIESON PW, COBBOLD SP, HALE G, et al: Monoclonal antibody therapy in systemic vasculitis. N Engl J Med 323:250, 1990
20. MESTRE M, BAS J, ALSINA J, et al: Depleting effects of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation. Transplant Proc 31:2254-2255, 1999
21. BURDICK JF: The biology of immunosuppression mediated by anti-lymphocyte antibodies, in Kidney Transplant Rejection: Diagnosis and Treatment, edited by William GM, Burdick JF, Solez K, New York, Marcel Dekker, 1986, pp 307-312
22. HOITSMA AJ, VAN LIER HJJ, REEKERS P, KOENE RAP: Improved patients and graft survival after treatment of acute rejections of cadaveric renal allografts with rabbit anticymocyte globulin. Transplantation 39:274, 1985
23. TARKOWSKI A, ANDERSON-GARE B, AURELL M: Use of antithymocyte globulin in the management of refractory systemic autoimmune diseases. Scand J Rheumatol 22:261-266, 1993
24. TARKOWSKI A, LINDGREN I: Beneficial effects of antithymocyte globulin in severe cases of progressive systemic sclerosis. Transplant Proc 26:3197-3199, 1994
25. STRATTON RJ, WILSON, H, BLACK CM: Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40:84-88, 2001
26. MORISHITA Y, MATSUKAWA Y, KURA Y, et al: antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia. J Int Med Res 25:219-223, 1997
27. HAGEN EC, DE KEIZER RJW, ANDRASSY K, et al: Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clinical Nephrology 43:351-359, 1995
28. DE GROOT K, GROSS WL, HERLYN K, REINHOLD-KELLER E: Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 55:31-38, 2001
29. KALLENBERG CGM: A disease activity index in Wegener's granulomatosis. APMIS 98 (Suppl 19):37-39, 1990
30. LUKAS R, KELLER F: Anti-thymocyte globulin therapy in a patient with pANCA vasculitis and crescentic glomerulonephritis [letter]. Nephron 78:231, 1998
31. KOOL J, DE KEIZER RJW, SIEGERT CEH: Antithymocyte globulin treatment of orbital Wegener granulomatosis: A follow-up study. Am J Opthalmol 127:738-739, 1999
32. MAILLARD N, FOUCHER P, CAILLOT D, et al: Transient pulmonary infiltrates during treatment with anti-thymocyte globulin. Respiration 66:279-282, 1999
33. SHORR, AF, ABOTT KC, AGADOA LY: Acute repiratory distress syndrome after kidney transplantation: Epidemiology, risk factors, and outcomers. Crit Care Med 31:1325-1330, 2003
34. BOCK HA, GALLATI H, ZURCHER RM, et al: A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation 59:830-840, 1995
35. VAN DER GELD YM, HUITEMA MG, FRANSSEN CFM, et al: In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis. Clin Exp Immunol 122:504-513, 2000
36. MASUTANI K, TOKUMOTO M, NAKASHIMA H, et al: Strong polarization toward Th1 immune response in ANCA-associated glomerulonaphritis. Clin Nephrol 59:395-405, 2003
37. TIPPING PG, KITCHING AR, CUNNINGHAM MA, HOLDSWORTH SR: Immunopathogenesis of crescentic glomerulonephritis. Curr Opin Nephrol Hypertens 8:281-286, 1999
38. LI S, HOLDSWORTH SR, TIPPING PG: Antibody independent crescentic glomerulonephritis in m chain deficient mice. Kidney Jnt 51:672-678, 1997
39. WU J, HICKS J, BORILLO J, et al: CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest 109:517-524, 2002
40. REYNOLDS J, NORGAN VA, BHAMBRA U, et al: Anti-Cd8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J Am Soc Nephrol 13:359-369, 2002
41. FURUTA T, HOTTA O, YUSA N, et al: Lymphocytapharesis to treat rapidly progressive glomerulonephritis: A randomised comparison with GC-pulse treatment [letter]. Lancet 352:203-204, 1998
42. NIKOLIC-PATERSON DJ, KERR PG, LAN HY, et al: Deoxyspergualin: A new immunosuppressive drug for the auto-immune disease. Nephron 70:391-396, 1995
43. BIRCK R, WARNATZ K, LORENZ HM, et al: 15-deoxyspergualin in patients with refractory ANCA associated systemic vasculitis. A six months open label trial to evaluate safety and efficacy. J Am Soc Nephrol 14:440-447, 2003
44. COUSER WG: Sensitized cells come of age: A new era in renal immunology with important therapeutic implications. J Am Soc Nephrol 10:664-665, 1999
45. XIAO H, HEERINGA P, HU P, et al: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955-963, 2002
46. SPECKS U, FERVENZA FC, MCDONALD TJ, HOGAN MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44:2836-2840, 2001
47. LAMPRECHT P, VOSSWINKEL J, LILIENTHAL T, et al: Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41:1303-1307, 2002
48. FARGE D, LEBBE C, MARJANOVIC Z, et al: Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Group Cooperatif de Transplantation d' Ile de France (GCIF). Transplantation 67:1236-1242, 1999